Fluidigm

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening

Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform

Fluidigm to Be Exclusive Distributor for Bethyl Antibodies for Use with Imaging Mass Cytometry

New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System

Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per Day

Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19

Study Suggests That Type I IFN Deficiency in the Blood Could Help Define a High-Risk Population Study Suggests That Type I IFN Deficiency in the Blood Could Help Define a High-Risk Population

University of Paris Researchers Utilize Fluidigm Mass Cytometry and  Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

Investors appear to be banking on the company winning FDA emergency use authorization for its Biomark system in COVID-19 testing.

Why Fluidigm Stock Is Soaring Again Today

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q1 2020 Results - Earnings Call Transcript

Custom Projects and Consultation from Experimental Panel Design to Data Analysis

Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services

Is  (FLDM) Outperforming Other Medical Stocks This Year?

Is Fluidigm (FLDM) Outperforming Other Medical Stocks This Year?

Expediting Treatment of COVID-19 Patients and Enhancing Testing Resources for Caregivers in Oklahoma

OU Medicine, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation File for FDA Emergency Use Authorization for COVID-19 Detection Test Utilizing Fluidigm Technology

SOUTH SAN FRANCISCO, Calif., April  14, 2020  (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today provided an update on the impact of the COVID-19 pandemic on its business and announced preliminary revenue estimates for the quarter ended March 31, 2020.

Fluidigm Provides Update on COVID-19 Impact and Preliminary Revenue Estimate for First Quarter 2020

Denny's

Ocugen, Inc.

Rocky Brands

Neuronetics Inc

Bet on these top--ranked stocks with rising P/E to realize outsized gains.

Snap Up These 5 Stocks With Rising P/E

SOUTH SAN FRANCISCO, Calif., April  02, 2020  (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® CyTOF® technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia

Speed and scale of Fluidigm microfluidics technology to facilitate early-stage host monitoring for COVID-19 Speed and scale of Fluidigm microfluidics technology to facilitate early-stage host monitoring for COVID-19

Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology

Driving Cell Capture to Insight with Precision, Speed and Simplicity to Accelerate Biomarker and Therapeutic Development Driving Cell Capture to Insight with Precision, Speed and Simplicity to Accelerate Biomarker and Therapeutic Development

Fluidigm Introduces AccuLift Laser Capture Microdissection System to Advance Translational and Clinical Pathology Research

Acquisition to expand Fluidigm’s industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep

Fluidigm Completes Acquisition of InstruNor AS

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q4 2019 Results - Earnings Call Transcript

Fluidigm (FLDM) delivered earnings and revenue surprises of 72.73% and 4.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Fluidigm (FLDM) Reports Q4 Loss, Tops Revenue Estimates

New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research

Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry

SOUTH SAN FRANCISCO, Calif., Feb.  10, 2020  (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™ Immune Profiling Assay™ to develop highly multiplexed immune profiling services.

Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services

Retrospective Clinical Study Uses Highly Multiplexed Imaging Mass Cytometry to Reveal Previously Unknown Features of the Tumor Microenvironment and Novel Breast Cancer Subgroups Retrospective Clinical Study Uses Highly Multiplexed Imaging Mass Cytometry to Reveal Previously Unknown Features of the Tumor Microenvironment and Novel Breast Cancer Subgroups

Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes

Fourth quarter preliminary revenue of $32.0-32.4 million

Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019

Fluidigm microfluidics technology to fuel growth in genomics services Fluidigm microfluidics technology to fuel growth in genomics services

MOgene Selects Fluidigm Advanta Assays and Juno System to Expand Its NGS Services Portfolio

SOUTH SAN FRANCISCO, Dec.  18, 2019  (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab, a hub for collaborative and innovative research at the intersection of synthetic biology, protein engineering and personalized medicine, has chosen the Hyperion™ Imaging System to expand its capabilities in multiparameter imaging and immune profiling of tissue.

The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping

Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies

Fluidigm Named to Greater Toronto's Top Employers for 2020

Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry

News for Fluidigm Stock (FLDM)